Revenue Management Experts

Alliance has the expertise to help you maximize revenue and optimize pricing.

Download a copy of our latest
revenue management white papers 

With the current focus on the repeal and replacement of the Affordable Care Act (ACA), several other significant elements of healthcare reform are being overlooked. One such regulation is the “340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties,” or 340B Final Rule for short, which was published in the Federal Register in January 2017.

Almost exclusively focused on pharmaceutical manufacturers, this directive concerns two important aspects of the 340B program: ceiling prices and civil monetary penalties. Seeking to clear up confusion caused by previous legislation, the act finalizes the methods by which companies must act in specific pricing scenarios. With the proposed date of enforcement only weeks away, manufacturers need to react quickly in order to adapt.

The Patient Protection and Affordable Care Act of 2010 considerably restructured the way in which healthcare is provided in the United States. Now, as congress plans its “repeal and replacement,”1 it may not be fruitful to speculate about potential superseding laws, but a reexamination of the parameters and impact of the Affordable Care Act (ACA) is appropriate. For pharmaceutical manufacturers, the changes brought on by the ACA were particularly substantial within their pricing, contracting, and revenue management divisions. Understanding these factors is critical to enable companies to better prepare for and respond to any forthcoming legislation, which appears to be rapidly approaching.
340B participation is mandatory for pharmaceutical manufacturers that take part in the Medicaid Drug Rebate program. However, vague program administration guidelines, coupled with a lack of effective oversight, has made managing the process difficult. This paper discusses business complications and compliance issues manufacturers need to address.
In November 2015, the Bipartisan Budget Act of 2015 was signed into law, bringing with it a host of changes for the scope and structure of a variety of governmental programs. One such affected entity is the Medicaid Drug Rebate Program. This amendment is particularly noteworthy for pharmaceutical manufacturers, not so much for its contents, but for the events influencing its speedy ratification.

The groups that comprise the Managed Markets division of a pharmaceutical manufacturer, despite their inherent overlap of job tasks, can often work in silos. Even when operating at full capacity, an exclusive focus on individual responsibilities can lead inevitably, and unknowingly, to downstream issues if not properly aligned with the needs of the other groups. Only when the Contract Management, Rebate Processing, and Government Pricing teams work harmoniously can optimal efficiency be achieved across the division.

The pressure on pharmaceutical manufacturers to meet statutory requirements for discount and liability accruals has never been greater, due largely to the increasing diversity and complexity of today’s marketing and contracting offerings. To meet this challenge,pharmcos are heavily investing time and resources to improve the gross-to-net (GTN) management process using forecasts to reconcile these items.Improving GTN management is not just about meeting statutory requirements. In fact, improvements in these areas can drive significant impacts in profit through a more robust understanding of the revenue and demand drivers, and how the discounts and liabilities affect these factors. In addition, greater accuracy in the accruals process leads to fewer adjustments, and greater predictability in cash flow.

The administrative tasks associated with rebate processing aren’t typically viewed as revenue generators for an organization. However, when managed effectively, these activities can undoubtedly provide considerable benefits to a company and contribute to the bottom line.  If left unattended or overlooked, a business can encounter compliance issues, misallocate time and resources, and suffer extensive financial losses. Consequently, a standardized rebate calculation process, coupled with validation and analytics, are necessary components of a successful practice. This paper explores how these procedures, when implemented appropriately, capture revenue leakage, measure efficiency, and provide real time insights needed for critical decision making.

A mid-market manufacturer’s contract management systems enviroment had functionality gaps in the areas of contract development, commercial rebate processing, admin fee calculations, operational and strategic reporting and workflow integration. The existence of these gaps necessitated excessive manual processing, which limited productivity and heightened regulatory compliance risk.

Learn more about our revenue management services 

Contract Lifecycle Management

Leading contract lifecycle management with measurable outcomes.

Gross-to-Net

Improve accrual forecasts and evolve your gross-to-net processes.

Membership Management

Technology-enabled data service for managing membership.

Business Process Outsourcing

Achieve operational excellence and keep costs down.